316 related articles for article (PubMed ID: 38257245)
1. Trabectedin and Lurbinectedin Modulate the Interplay between Cells in the Tumour Microenvironment-Progresses in Their Use in Combined Cancer Therapy.
Povo-Retana A; Landauro-Vera R; Alvarez-Lucena C; Cascante M; Boscá L
Molecules; 2024 Jan; 29(2):. PubMed ID: 38257245
[TBL] [Abstract][Full Text] [Related]
2. Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.
Belgiovine C; Bello E; Liguori M; Craparotta I; Mannarino L; Paracchini L; Beltrame L; Marchini S; Galmarini CM; Mantovani A; Frapolli R; Allavena P; D'Incalci M
Br J Cancer; 2017 Aug; 117(5):628-638. PubMed ID: 28683469
[TBL] [Abstract][Full Text] [Related]
3. Trabectedin and lurbinectedin: Mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma.
Gadducci A; Cosio S
Front Oncol; 2022; 12():914342. PubMed ID: 36408147
[TBL] [Abstract][Full Text] [Related]
4. Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein.
Erba E; Romano M; Gobbi M; Zucchetti M; Ferrari M; Matteo C; Panini N; Colmegna B; Caratti G; Porcu L; Fruscio R; Perlangeli MV; Mezzanzanica D; Lorusso D; Raspagliesi F; D'Incalci M
Biochem Pharmacol; 2017 Nov; 144():52-62. PubMed ID: 28782526
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.
Lima M; Bouzid H; Soares DG; Selle F; Morel C; Galmarini CM; Henriques JA; Larsen AK; Escargueil AE
Oncotarget; 2016 May; 7(18):25885-901. PubMed ID: 27029031
[TBL] [Abstract][Full Text] [Related]
6. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
7. Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.
Carter NJ; Keam SJ
Drugs; 2010 Feb; 70(3):355-76. PubMed ID: 20166769
[TBL] [Abstract][Full Text] [Related]
8. Immunometabolic actions of trabectedin and lurbinectedin on human macrophages: relevance for their anti-tumor activity.
Povo-Retana A; Fariñas M; Landauro-Vera R; Mojena M; Alvarez-Lucena C; Fernández-Moreno MA; Castrillo A; de la Rosa Medina JV; Sánchez-García S; Foguet C; Mas F; Marin S; Cascante M; Boscá L
Front Immunol; 2023; 14():1211068. PubMed ID: 37675104
[TBL] [Abstract][Full Text] [Related]
9. Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer.
Monk BJ; Dalton H; Benjamin I; Tanović A
Curr Pharm Des; 2012; 18(25):3754-69. PubMed ID: 22591421
[TBL] [Abstract][Full Text] [Related]
10. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
[TBL] [Abstract][Full Text] [Related]
11. Lurbinectedin: A New Treatment Option for Relapsed/Refractory Small-Cell Lung Cancer.
Shinn LT; Vo KA; Reeves DJ
Ann Pharmacother; 2021 Sep; 55(9):1172-1179. PubMed ID: 33348988
[TBL] [Abstract][Full Text] [Related]
12. The Antitumor Drugs Trabectedin and Lurbinectedin Induce Transcription-Dependent Replication Stress and Genome Instability.
Tumini E; Herrera-Moyano E; San Martín-Alonso M; Barroso S; Galmarini CM; Aguilera A
Mol Cancer Res; 2019 Mar; 17(3):773-782. PubMed ID: 30552231
[TBL] [Abstract][Full Text] [Related]
13. Lurbinectedin for the treatment of small cell lung cancer.
Li L; Zou C; Dong S; Wu ZX; Ashby CR; Chen ZS; Qiu C
Drugs Today (Barc); 2021 Jun; 57(6):377-385. PubMed ID: 34151904
[TBL] [Abstract][Full Text] [Related]
14. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
15. Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin - activity against ovarian cancer cells.
Marczak A; Denel M
Contemp Oncol (Pozn); 2014; 18(3):149-52. PubMed ID: 25520572
[TBL] [Abstract][Full Text] [Related]
16. Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer.
Del Campo JM; Muñoz-Couselo E; Diaz de Corcuera I; Oaknin A
Expert Rev Anticancer Ther; 2010 Jun; 10(6):795-805. PubMed ID: 20553205
[TBL] [Abstract][Full Text] [Related]
17. A review of trabectedin (ET-743): a unique mechanism of action.
D'Incalci M; Galmarini CM
Mol Cancer Ther; 2010 Aug; 9(8):2157-63. PubMed ID: 20647340
[TBL] [Abstract][Full Text] [Related]
18. A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas.
Cote GM; Choy E; Chen T; Marino-Enriquez A; Morgan J; Merriam P; Thornton K; Wagner AJ; Nathenson MJ; Demetri G; George S
Eur J Cancer; 2020 Feb; 126():21-32. PubMed ID: 31896519
[TBL] [Abstract][Full Text] [Related]
19. Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).
Romano M; Frapolli R; Zangarini M; Bello E; Porcu L; Galmarini CM; García-Fernández LF; Cuevas C; Allavena P; Erba E; D'Incalci M
Int J Cancer; 2013 Nov; 133(9):2024-33. PubMed ID: 23588839
[TBL] [Abstract][Full Text] [Related]
20. Lurbinectedin in the treatment of relapsed small cell lung cancer.
Baena J; Modrego A; Zeaiter A; Kahatt C; Alfaro V; Jimenez-Aguilar E; Mazarico JM; Paz-Ares L
Future Oncol; 2021 Jun; 17(18):2279-2289. PubMed ID: 33736462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
